Keymed Biosciences Inc (HKSE:02162) Share Price

Company Profile

Business description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact
No. 18 BioTown Middle Road
Building D2
Tianfu International BioTown, Chengdu
Sichuan610219
CHN
T: +86 2888610620
https://www.keymedbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,469

Recommended

The magnitude of growth at Broadcom continues to astound us.

William Kerwin, CFA | 10 September 2025

The banking major needs to prevent key product offerings from falling further behind the competition.

Nathan Zaia | 10 September 2025

A great fiscal 2025 but investors are ahead of themselves.

Mark Taylor | 08 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,090.00	23.60	0.26%
CAC 40	7,749.39	14.55	0.19%
DAX 40	23,718.45	88.68	-0.37%
Dow JONES (US)	45,711.34	196.39	0.43%
FTSE 100	9,242.53	21.09	0.23%
HKSE	26,246.13	308.00	1.19%
NASDAQ	21,879.49	80.79	0.37%
Nikkei 225	43,765.41	306.12	0.70%
NZX 50 Index	13,268.34	14.61	0.11%
S&P 500	6,512.61	17.46	0.27%
S&P/ASX 200	8,824.40	34.00	0.39%
SSE Composite Index	3,813.78	6.49	0.17%